SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

The word "Markets Insider". CHENGDU, China, May 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to ...

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing ...

WuXi Biologics is giving CDMO Terumo the keys to its site in Leverkusen, Germany, with a 150 million euros ($167 million) sale. With the deal, WuXi Biologics can “exclusively focus” on ...

WuXi Biologics will look to produce about 36,000 liters of pharmaceutical products from the 24,000 liters it announced in 2022, when work started toward its 189,500-square-foot project that is ...